Does Cigna Cover Wegovy? Express Scripts PA, Plan Design, and the Appeal Math

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

As of May 2026. Confirm directly with your plan. Coverage varies by employer plan, region, and time. Always confirm with your specific plan administrator.

Key Takeaways

• Cigna commercial plans cover Wegovy with PA through Express Scripts when the employer plan includes weight-loss drug benefits
• Express Scripts is owned by Evernorth Health Services, Cigna's parent-side subsidiary. The PBM and insurer share an integrated workflow
• PA criteria track FDA labeling: BMI 30+, or BMI 27+ with comorbidity, plus lifestyle intervention documentation
• Cigna Healthspring Medicare Advantage covers Wegovy only for the cardiovascular indication after the November 2024 CMS rule
• Step therapy with Saxenda applies on some Cigna plans; exceptions are available with clinical reasoning

Direct answer

Cigna commercial plans cover Wegovy for adults with obesity or overweight with a weight-related comorbidity when the Express Scripts prior authorization is approved and the employer plan includes weight-loss drug coverage. As of May 2026, the PA requires BMI documentation, comorbidity (when BMI is 27 to 29.9), and lifestyle intervention. Cigna Medicare Advantage covers Wegovy only for the FDA-approved cardiovascular indication.

Table of contents

1. Cigna and Express Scripts: how the relationship works for Wegovy
2. Cigna's Wegovy PA criteria
3. BMI documentation requirements
4. Comorbidity for BMI 27 to 29.9 patients
5. Lifestyle intervention documentation
6. Step therapy with Saxenda on some Cigna plans
7. Renewal at 6 months: the 5% weight-loss benchmark
8. Employer plan layering: the deciding factor
9. Cigna Medicare Advantage and the cardiovascular indication
10. Cost-sharing math with and without coverage
11. Reading the Express Scripts denial letter
12. Building the appeal that gets reviewed
13. External review under the ACA
14. When Cigna says no: alternatives including 503A compounded
15. Contrary view: defensible reasons for tight Wegovy PA
16. Decision framework
17. FAQ
18. Sources

Cigna and Express Scripts: how the relationship works for Wegovy

Cigna acquired Express Scripts in 2018. The PBM now operates under the Evernorth Health Services umbrella. For Wegovy, this means Express Scripts processes the pharmacy claim, adjudicates the PA, and issues the denial or approval. Cigna sets the formulary policy that Express Scripts applies.

The integration is similar to UnitedHealthcare and OptumRx. Customer service routing depends on whether your question is about benefit design (Cigna) or pharmacy claim handling (Express Scripts). Wegovy PA questions typically route through Express Scripts.

Cigna's Wegovy PA criteria

The Cigna Wegovy PA, administered by Express Scripts, asks for:

• Patient and prescriber information
• Diagnosis with ICD-10 code (E66.x or specific comorbidity)
• Current BMI with measurement date, height, and weight
• Age 18 or older for the adult indication
• Comorbidity diagnoses with supporting evidence (for BMI 27 to 29.9)
• Lifestyle intervention history with dates and outcomes
• Step therapy compliance where applicable
• Quantity requested within the standard quantity limit

The PA is submitted by the prescriber through the Express Scripts provider portal or by fax. Decisions arrive within 72 hours standard, 24 hours expedited.

BMI documentation requirements

BMI is the gatekeeper for Wegovy coverage. Express Scripts wants:

• The measurement date (recent, not stale)
• Height and weight values (so BMI can be verified)
• Calculated BMI
• The measurement context (clinical visit, not self-reported)

BMI of 30 or higher qualifies for the obesity indication. BMI 27 to 29.9 qualifies for the overweight indication with comorbidity. BMI below 27 does not qualify.

Comorbidity for BMI 27 to 29.9 patients

The accepted comorbidities for the overweight indication:

• Type 2 diabetes
• Hypertension
• Dyslipidemia
• Obstructive sleep apnea
• Cardiovascular disease
• Non-alcoholic fatty liver disease (on some plans)

The comorbidity must be current and documented. Stale or unsupported diagnoses raise reviewer concerns. The PA reviewer often wants to see lab values, BP readings, sleep study reports, or specialist notes that confirm the comorbidity is active.

Lifestyle intervention documentation

Cigna's Wegovy PA requires lifestyle intervention documentation. Acceptable evidence:

• Commercial weight-loss program enrollment records
• Dietitian or nutritionist visit notes
• Behavioral health visits addressing eating patterns
• Detailed primary care chart notes on weight management
• Cigna's own wellness program engagement records (some employer plans have specific programs)

Some plans require 3 to 6 months of documented prior attempts. Others accept concurrent engagement. The PA criteria for the specific plan specify the requirement.

Step therapy with Saxenda on some Cigna plans

Some Cigna plans require a Saxenda trial before Wegovy. Saxenda is liraglutide, a daily injection GLP-1 in the same drug class but at a lower per-fill cost.

Step-therapy exceptions are available with documented reasoning:

• Prior Saxenda trial with inadequate response or intolerance
• Contraindication
• Patient-specific clinical reason (daily injection adherence concerns, history of injection-site reactions)

The exception request goes through Express Scripts on the same PA form.

Renewal at 6 months: the 5% weight-loss benchmark

Cigna's Wegovy renewal criteria typically require 5% weight loss from baseline at 6 months. The renewal PA documents:

• Baseline weight at start of therapy
• Current weight
• Percentage weight loss
• Continued lifestyle engagement
• Continued tolerability

The 5% threshold matches FDA labeling guidance for continuation of obesity pharmacotherapy. Patients who do not meet the threshold may be declined renewal unless dose-titration trajectory or other clinical factors justify continued therapy.

Employer plan layering: the deciding factor

Cigna administers many self-funded employer plans. Under ERISA, the employer sets the benefit design. The same Cigna card across two employers can produce different Wegovy coverage outcomes.

Common employer plan configurations:

• Cigna standard PA with weight-loss drug coverage included
• Employer exclusion of weight-loss drugs entirely
• Modified PA with stricter or looser criteria than Cigna standard
• Coverage tied to employer-sponsored weight-management program

The Summary of Benefits and Coverage and Evidence of Coverage are authoritative.

Cigna Medicare Advantage and the cardiovascular indication

Cigna Healthspring Medicare Advantage plans cover Wegovy only for the cardiovascular indication, following the November 2024 CMS final rule. Criteria:

• Documented established cardiovascular disease
• BMI 27 or higher
• Prescription written for the cardiovascular indication
• Standard Part D PA met

The Part D $2,000 annual OOP cap applies. The manufacturer card is not available to Medicare beneficiaries.

Cost-sharing math with and without coverage

Scenario	Approximate monthly cost
Cigna commercial, Wegovy covered, with manufacturer card	$0 to $25 (eligibility, annual cap)
Cigna commercial, Wegovy covered, no card	$25 to $200 copay
Cigna commercial, Wegovy not covered, with card	~$650 cash-pay (terms vary)
Cigna commercial, Wegovy not covered, no card	$1,300 to $1,450 cash
Cigna Medicare Advantage, CV indication	$50 to $150, up to $2,000 OOP cap
Cigna Medicare Advantage, weight loss only	Not covered

Reading the Express Scripts denial letter

Express Scripts Wegovy denial letters for Cigna claims are structured. Common categories:

• "BMI does not meet plan criteria." BMI documentation showed below threshold, or BMI 27 to 29.9 without comorbidity.
• "Lifestyle intervention not documented." The PA did not include the lifestyle documentation.
• "Plan benefit does not cover weight-loss drugs." Employer exclusion.
• "Step therapy required." Saxenda or another preferred drug not tried.
• "Documentation insufficient." PA missing required elements.
• "Quantity limit exceeded." Standard quantity is one pen per 28 days at maintenance dose.

Building the appeal that gets reviewed

Express Scripts Wegovy appeals get reviewed by clinical pharmacists or medical directors. The strongest appeals address the specific denial reason with specific evidence.

For a BMI denial, recheck the documentation and confirm the BMI is correctly recorded.

For a comorbidity denial, submit the chart notes, lab values, or specialist reports that establish the comorbidity is active.

For a lifestyle intervention denial, submit the documentation that was missing: program enrollment records, dietitian notes, behavioral health visits, or detailed chart notes from primary care visits.

For a step-therapy denial, either document the Saxenda trial or file the exception with clinical reasoning.

For an employer exclusion denial, internal appeal will not overturn the exclusion.

External review under the ACA

If Cigna upholds the denial on internal appeal, external review under ACA Section 2719 applies for most commercial plans. The reviewer is an independent physician with relevant specialty. The decision is binding on Cigna.

The deadline is typically 4 months from the final internal denial. State variation matters; some states (NY, CA, others) run their own external review processes.

When Cigna says no: alternatives including 503A compounded

If Cigna will not cover Wegovy and the manufacturer card or patient assistance program cannot bridge the cost, 503A compounded semaglutide via telehealth is one path to GLP-1 therapy.

503A compounded semaglutide is the same active molecule but is not FDA-approved and is not equivalent to brand-name Wegovy. The product is prepared individually for each patient by a state-licensed 503A pharmacy. FormBlends works with state-licensed 503A pharmacies and licensed clinicians.

The compounded path is cash-pay. It is not billable to Cigna or any commercial insurer.

Contrary view: defensible reasons for tight Wegovy PA

Cigna's Wegovy PA can feel onerous to patients who would benefit. The actuarial argument: Wegovy at retail is approximately $1,350 per month. Plan-level cost grows quickly with broad uptake. The PA criteria, including the 5% renewal threshold, screen for clinical fit and continued response.

The argument against: PA imposes friction that delays care. Approval rates after appeals are high for clinically appropriate patients, raising the question of whether the upfront PA serves a clinical purpose or just a friction function. The clinical guidelines (Endocrine Society, Obesity Society) recommend pharmacotherapy as a second-line intervention after lifestyle alone fails, which Cigna's criteria roughly track. Reasonable people disagree on the right balance.

Decision framework

If your Cigna plan covers weight-loss drugs and you meet BMI criteria: file the PA. Build the file with BMI documentation, comorbidity diagnoses (for BMI 27 to 29.9), and lifestyle intervention history.

If your Cigna employer plan excludes weight-loss drugs: internal appeal will not overturn the exclusion. Pursue manufacturer card, patient assistance, or 503A.

If you are on Cigna Healthspring MA with cardiovascular disease: Wegovy may be coverable under the November 2024 CMS rule for the CV indication.

If you are approaching 6-month renewal: document the weight loss and lifestyle engagement. The 5% threshold matters.

FAQ

Does Cigna cover Wegovy? On plans with weight-loss drug coverage, yes with PA. On plans without, no.

What's the BMI threshold? 30+, or 27+ with comorbidity.

How long is initial approval? 6 months typically.

Renewal criterion? 5% weight loss from baseline.

Step therapy? Some plans require Saxenda first.

Does Cigna Medicare Advantage cover Wegovy? Only for the cardiovascular indication.

How do I appeal? File with Cigna or Express Scripts within the deadline. Address the specific denial reason.

Sources

1. Cigna commercial formulary documents. 2026.
2. Express Scripts clinical policy: Wegovy and GLP-1 for chronic weight management. 2026.
3. Cigna Evernorth Health Services overview.
4. U.S. Food and Drug Administration. Wegovy prescribing information.
5. Lincoff AM, et al. SELECT cardiovascular outcomes. NEJM. 2023;389:2221-2232.
6. Wilding JPH, et al. STEP 1. NEJM. 2021;384:989-1002.
7. Rubino D, et al. STEP 4. JAMA. 2021;325:1414-1425.
8. Centers for Medicare and Medicaid Services. Final rule on Part D for cardiovascular indications. November 2024.
9. Affordable Care Act, Section 2719 external review.
10. Endocrine Society. Obesity pharmacotherapy clinical practice guideline.
11. Novo Nordisk. Wegovy Savings Card program terms.
12. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians. We do not adjudicate Cigna or Express Scripts claims. Information here reflects publicly available materials as of May 2026 and is subject to change.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy on individual prescriptions. It is not FDA-approved, is not equivalent to brand-name Wegovy, and is not billable to Cigna. A prescribing clinician should be involved in the decision.

Results Disclaimer. Coverage and weight-loss outcomes depend on plan rules, clinical situation, and individual response. The examples here do not predict outcomes for any specific case.

Trademark Notice. Cigna and Evernorth Health Services are registered trademarks of The Cigna Group. Express Scripts is a registered trademark of Express Scripts Holding Company. Wegovy, Saxenda, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is independent.